Skip to content
Screener

Glaukos GKOS Interest Expense

Interest Expense at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$281M-8.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$11M+206%
Sight Sciences, Inc. logo
Sight Sciences, Inc.SGHT
$1.29M+0.5%
Bausch + Lomb logo
Bausch + LombBLCO
$93M-27.3%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$2.78M-6.9%
HRO
HarrowHROW
$5.5M-16.1%

Segments

By segment

See full
Development And Commercialization Of Ophthalmic Therapies-$1.46M-227%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Loss from operations(17,267)(22,689)(37,123)(43,367)
Non-operating income (expense):
Interest income2,2792,5744,7105,650
Interest expense(1,459)(1,151)(2,584)(2,314)
Other (expense) income, net(1,274)1,857(2,023)2,802
Total non-operating (expense) income(454)3,2801036,138
Loss before taxes(17,721)(19,409)(37,020)(37,229)
Income tax provision6562481,140574

Item 1. Financial Statements

FAQ

What is Glaukos's interest expense?
Glaukos (GKOS) reported interest expense of $1.46M in Q2 2026.
How has Glaukos's interest expense changed year-over-year?
Glaukos's interest expense increased by 26.8% year-over-year, from $1.15M to $1.46M.
What is the long-term trend for Glaukos's interest expense?
Over 4 years (2021 to 2025), Glaukos's interest expense has grown at a -23.3% compound annual growth rate (CAGR), from $13.37M to $4.64M.
What does interest expense mean?
Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.

Ask your AI about Glaukos's interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude